OmniAb (OABI) Intangibles (2021 - 2026)
OmniAb (OABI) posted quarterly Intangibles of $119.1 million for Q1 2026, down 11.65% year-over-year from $134.8 million in Q1 2025, and down 4.82% quarter-over-quarter from $125.1 million in Q4 2025.
OmniAb (OABI) Intangibles (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Intangibles for 6 consecutive years, with $119.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles fell 11.65% year-over-year to $119.1 million; the TTM figure through Mar 2026 stood at $119.1 million (down 11.65% YoY), while the FY2025 annual figure was $125.1 million, down 9.35% from the prior year.
- Intangibles declined to $119.1 million in Q1 2026 per OABI's latest filing, from $125.1 million in the prior quarter.
- Across five years, Intangibles topped out at $167.2 million in Q4 2022 and bottomed at $119.1 million in Q1 2026.
- Historically, Intangibles has averaged $144.9 million across 5 years, with a median of $145.8 million in 2024.
- Annual changes were most pronounced in 2022 — Intangibles slipped 5.15% — and 2026, when it slipped 11.65%.
- OmniAb's Intangibles stood at $167.2 million in 2022, then retreated by 7.04% to $155.5 million in 2023, then retreated by 11.2% to $138.1 million in 2024, then dropped by 9.35% to $125.1 million in 2025, then slipped by 4.82% to $119.1 million in 2026.
- Business Quant data shows OABI's Intangibles at $119.1 million in Q1 2026, $125.1 million in Q4 2025, and $128.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | 116.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 116.07 Mn |
| Mar 31, 2026 | 119.12 Mn |
| Dec 31, 2025 | 125.15 Mn |
| Sep 30, 2025 | 128.38 Mn |
| Jun 30, 2025 | 131.61 Mn |
| Mar 31, 2025 | 134.83 Mn |
| Dec 31, 2024 | 138.06 Mn |
| Sep 30, 2024 | 144.12 Mn |
| Jun 30, 2024 | 147.51 Mn |
| Mar 31, 2024 | 152.06 Mn |
| Dec 31, 2023 | 155.47 Mn |
| Sep 30, 2023 | 158.77 Mn |
| Jun 30, 2023 | 161.92 Mn |
| Mar 31, 2023 | 164.36 Mn |
| Dec 31, 2022 | 167.24 Mn |
| Dec 31, 2021 | 176.32 Mn |